Versant Venture Capital — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Santa Ana Biosantaanabio.cominFeb 2023SEC filinghigh confidence
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)
Board seatJerel DavisThomas Woiwode· per SEC Form D · $70.3M raise · filed Feb 2023
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.